Increased expression of the antiapoptotic protein MCL1 in canine mast cell tumors

Journal of Veterinary Medical Science

Volumn 75, Issue 7, 2013, Pages 971-974

  Amagai, Yosuke ^a   Tanaka, Akane ^a   Matsuda, Akira ^a   Oida, Kumiko ^a   Jung, Kyungsook ^a   Nishikawa, Sho ^a   Jang, Hyosun ^a   Ishizaka, Saori ^a   Matsuda, Hiroshi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Mast cell tumor; MCL1

Indexed keywords

EID: 84880961419     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.13-0025     Document Type: Note

References (25)

1. Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Müllauer, L., Agis, H., Sillaber, C. and Valent, P. 2007. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC 412. Blood 109: 3031-3041. [Medline]
2. Akgul, C. 2009. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 66: 1326-1336. [Medline] [CrossRef]
3. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. and Saltiel, A. R. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270: 489-494. [Medline]
4. Amagai, Y., Tanaka, A., Matsuda, A., Oida, K., Jung, K. and Matsuda, H. The phosphoinositide 3-kinase pathway is crucial for the growth of canine mast cell tumors. J. Vet. Med. (in press).
5. Blackwood, L., Murphy, S., Buracco, P., De Vos, J. P., De Fornel-Thibaud, P., Hirschberger, J., Kessler, M., Pastor, J., Ponce, F., Savary-Bataille, K. and Argyle, D. J. 2012. European consensus document on mast cell tumours in dogs and cats. Vet. Comp. Oncol. 10: e1-e29. [Medline] [CrossRef]
6. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S. and Schreiber, S. L. 1994. A mammalian protein target by G1-arresting rapamycin-receptor complex. Nature 369: 756-758. [Medline] [CrossRef]
7. Caughey, G. H., Lazarus, S. C., Viro, N. F., Gold, W. M. and Nadel, J. A. 1988. Tryptase and chymase: comparison of extraction and release in two dog mastocytoma lines. Immunology 63: 339-344. [Medline]
8. Evan, G. I. and Vousden, K. H. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348. [Medline] [CrossRef]
9. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A. and Zigler, A. J. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932. [Medline]
10. Kuramoto, K., Sakai, A., Shigemasa, K., Takimoto, Y., Asaoku, H., Tsujimoto, T., Oda, K., Kimura, A., Uesaka, T., Watanabe, H. and Katoh, O. 2002. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br. J. Haematol. 116: 158-161. [Medline] [CrossRef]
11. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. and Craig, R. W. 1993. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL 2. Proc. Natl. Acad. Sci. U. S. A. 90: 3516-3520. [Medline] [CrossRef]
12. Matsuda, A., Tanaka, A., Amagai, Y., Ohmori, K., Nishikawa, S., Xia, Y., Karasawa, K., Okamoto, N., Oida, K., Jang, H. and Matsuda, H. 2011. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Vet. Immunol. Immunopathol. 144: 321-328. [Medline] [CrossRef]
13. Mills, J. R., Hippo, Y., Robert, F., Chen, S. M., Malina, A., Lin, C. J., Trojahn, U., Wendel, H. G., Charest, A., Bronson, R. T., Kogan, S. C., Nadon, R., Housman, D. E., Lowe, S. W. and Pelletier, J. 2008. mTORC1 promotes survival through trans lational control of Mcl-1. Proc. Natl. Acad. Sci. U. S. A. 105: 10853-10858. [Medline] [CrossRef]
14. Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R., Tidd, D. M. and Edwards, S. W. 2000. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 Cells. Blood 96: 1756-1763. [Medline]
15. O'Driscoll, L., Cronin, D., Kennedy, S. M., Purcell, R., Linehan, R., Glynn, S., Larkin, A., Scanlon, K., McDermott, E. W., Hill, A. D., O'Higgins, N. J., Parkinson, M. and Clynes, M. 2004. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res. 24: 473-482. [Medline]
16. Ohmori, K., Kawarai, S., Yasuda, N., Tanaka, A., Matsuda, H., Nishimura, R., Sasaki, N., Tsujimoto, H. and Masuda, K. 2008. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet. Immunol. Immunopathol. 126: 43-53. [Medline] [CrossRef]
17. Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C. and Korsmeyer, S. J. 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671-676. [Medline] [CrossRef]
18. Shigemasa, K., Katoh, O., Shiroyama, Y., Mihara, S., Mukai, K., Nagai, N. and Ohama, K. 2002. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn. J. Cancer Res. 93: 542-550. [Medline] [CrossRef]
19. Stam, R. W., Den Boer, M. L., Schneider, P., de Boer, J., Hagelstein, J., Valsecchi, M. G., de Lorenzo, P., Sallan, S. E., Brady, H. J., Armstrong, S. A. and Pieters, R. 2010. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 115: 1018-1025. [Medline] [CrossRef]
20. Strasser, A. 2005. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 5: 189-200. [Medline] [CrossRef]
21. Tanaka, A., Konno, M., Muto, S., Kambe, N., Morii, E., Nakahata, T., Itai, A. and Matsuda, H. 2005. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324-2331. [Medline] [CrossRef]
22. Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269: 5241-5248. [Medline]
23. Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., Belmont, L. D., Kaminker, J. S., O'Rourke, K. M., Pujara, K., Kohli, P. B., Johnson, A. R., Chiu, M. L., Lill, J. R., Jackson, P. K., Fairbrother, W. J., Seshagiri, S., Ludlam, M. J., Leong, K. G., Dueber, E. C., Maecker, H., Huang, D. C. and Dixit, V. M. 2011. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW 7. Nature 471: 110-114. [Medline] [CrossRef]
24. Zhou, P., Qian, L., Kozopas, K. M. and Craig, R. W. 1997. Mcl- 1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89: 630-643. [Medline]
25. Zhou, P., Qian, L., Bieszczad, C. K., Noelle, R., Binder, M., Levy, N. B. and Craig, R. W. 1998. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92: 3226-3239. [Medline]